Abstract:Objective:To prospectively observe the clinical efficacy and safety of corticosteroids in combination with mycophenolate mofetil dispersible tablets(Cicopin~,MMF,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd) and tacrolimus(FK506,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd)(multi-target group) in the induction treatment for lupus nephritis(LN).Methodology:Seventy-nine patients with biopsy confirmed class IV,V+IV and V+III LN were randomly assigned to either multi-target group [n=45,39 females,6 males,mean age(25.1±9.3) years] or intravenous cyclophosphamide pulse therapy(IV-CYC) [n=34,30 females,4 males,mean age(30.4±8.9) years].All patients received intravenous methylprednisolone pulse therapy followed by oral prednisone.In multi-target group,the dose of MMF and FK506 was adjusted based on the blood level with the MPA-AUC0～12h level of 20～30 mg o h/L and FK506 trough level 4～7 ng/ml.In IV-CYC group,CYC was given in a dose 0.5～0.75 g/m2BSA monthly.The induction period was 6months to 9 months according to the responses on the therapy.The primary efficacy parameter was complete remission rate(defined as urine protein 0.4 g/24h,serum albumin ≥35 g/l,normal serum creatinine and no extra-renal activity),the secondary parameters were partial remission rate(defined as urinary protein less than the base value of 50% or more,and urine protein 3.5 g/24h,serum albumin ≥30 g/l,and serum creatinine stable) and incidence of adverse reactions.The clinical efficacy and adverse events were compared between two groups.Results:The baseline clinical and histological classes had no significant differences between multi-target group and IV-CYC group.The accumulated complete remission rate of multi-target group was significantly higher than that of IV-CYC group(P0.05) during the induction period.At 6months and 9 months,the complete remission rate was 53.3% and 62.2% respectively in the multi-target group,and 29.4% and 42.6%,in IV-CYC group respectively.Also,multi-target therapy showed much higher complete remission rate than IV-CYC therapy for class V+IV(50.0% vs 16.7%,P0.05) and class V+III(54.5% vs 22.2 %,P0.05).In class IV LN,no difference of the remission rate was found between the two groups.The incidence of adverse events in the multi-target group was much lower than that in the IV-CYC group(31.1% vs 70.6%,P0.01),the major adverse events were new-onset hypertension(11.1%) and herpes zoster(6.7%) in the multi-target group;while gastrointestinal reactions(23.5%),leukopenia(13.7%) and skin infections(8.8%) in the IV-CYC group.Three patients(2 in multi-target group and 1 in IV-CYC group) complicated with pulmonary infection,but none died.Conclusion:The multi-target therapy,which is composed of corticosteroids with Cicopin and tacrolimus,showed more effective than intravenous CYC pulse therapy in inducing remission of lupus nephritis,especially class V+IV,and had a more favorable safety.However,multi-center clinical trials are encouraged to evaluate the clinical efficacy and the impact on long-term survival for lupus nephritis.

FP136GLUCOCORTICOID MONOTHERAPY VERSUS COMBINATION IMMUNOSUPPRESSIVE THERAPY IN INDUCING AND MAINTAINING REMISSION FOR PATIENTS WITH LUPUS PODOCYTOPATHY

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Multitarget Therapy For Maintenance Treatment Of Lupus Nephritis

A Prospective Clinical Trail of Corticosteroids in Combination with Mycophenolate Mofetil Dispersible Tablets and Tacrolimus for the Induction Treatment of Lupus Nephritis

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Leflunomide Versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: a Randomized Trial.

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Successful Glucocorticoid Withdrawal in Chinese Lupus Nephritis Patients: A Single Centre Experience

Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial

Prospective Study of Tacrolimus Induction Regime for Diffuse Proliferative Lupus Nephritis

Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial

Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy

Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta‐analysis of the control arms of randomized controlled trials

Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort

Efficacy and long-term prognosis of mycophenolate mofetil treatment on patients with proliferative lupus nephritis

Comparison of tacrolimus with or without prednisone therapy in primary membranous nephropathy: a retrospective clinical study

Flare Rates and Factors Determining Flare Occurrence in Patients with Systemic Lupus Erythematosus Who Achieved Low Disease Activity or Remission: Results from a Prospective Cohort Study